Embolization Coils Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Embolization Coils Market Trends and Insights

Rising Neurovascular Aneurysm and AVM Treatment Volumes

Intracranial aneurysm embolization remained a key demand driver for the Embolization coils market. Wider access to computed tomography angiography and magnetic resonance angiography increased aneurysm detection among patients without emergency presentations. This expanded the pool of patients eligible for planned neurovascular intervention. The World Health Organization’s 2025 report identified stroke as the leading neurological contributor to global health loss, while the Stroke Alliance reported that the direct cost of 24 brain disorders exceeded USD 1.7 trillion.^{[1]Stroke Alliance for Europe, “New WHO Report Underscores Urgent Need for Action on Stroke,” Stroke Alliance for Europe}

The expansion of stroke centers across Asia-Pacific, the Middle East, and Africa strengthened the clinical infrastructure for aneurysm and arteriovenous malformation procedures. The American Heart Association reported continued growth in endovascular therapy use for acute ischemic stroke during a six-year national analysis. This trend showed that catheter-based neurovascular care had become more established within hospital treatment pathways.

Preference for Minimally Invasive Endovascular Procedures

Endovascular embolization was often preferred over surgical ligation or craniotomy because it reduced hospitalization and recovery time. In suitable patients, it also reduced intensive care resource utilization. These clinical and operational benefits supported catheter-based procedures as healthcare systems managed capacity and costs. The Embolization coils market benefited as coils remained integral to aneurysm and vessel occlusion procedures.

Training also reinforced the shift toward endovascular care. As hospitals established interventional radiology and interventional neurology fellowship programs, the number of qualified operators increased. A larger trained workforce reduced the concentration of complex coiling procedures in a limited number of tertiary hospitals. OECD data showed that ischemic stroke case-fatality rates declined across member countries between 2013 and 2019 as improvements in reperfusion therapy delivery coincided with wider endovascular use.

Expansion of Interventional Radiology and Stroke-Care Infrastructure

Healthcare investments across Asia-Pacific, the Middle East, and South America reduced structural barriers to coil adoption. New imaging capacity, catheter laboratories, and stroke programs enabled complex embolization procedures to become more routine. The Embolization coils market expanded as these clinical capabilities became available beyond long-established centers. However, trained operators remained necessary for sustained procedural adoption.

Reimbursement policy remained as important as physical device availability. Japan’s national insurance coverage for NUMEN coils supported commercial access across more than 250 hospitals. This demonstrated that payment coverage influenced product adoption in clinical practice. Japan and South Korea remained mature healthcare systems where physicians sought premium coil performance, while India and China were volume-driven markets where accessible pricing influenced early adoption.

Increased Use of Coils in Peripheral Hemorrhage and Oncology Embolization

The Embolization coils market gained demand from applications beyond the neurovascular setting. Transcatheter procedures for hepatocellular carcinoma, splenic artery aneurysms, postsurgical hemorrhage, and prostate artery embolization expanded coil use across interventional radiology programs. Providers increasingly performed these procedures in community settings and academic medical centers. This broadened the addressable patient base for vendors offering suitable peripheral products.

Selected lower-acuity peripheral procedures shifted from hospital catheter laboratories to ambulatory surgical centers when case complexity permitted. These settings favored standardized procedure kits and efficient device selection. Pushable coils and small-diameter detachable coils met these requirements when repositioning was less critical. Manufacturers that tailored packaging and delivery systems to outpatient workflows were better positioned in this channel.

High Device and Procedure Costs

Premium detachable systems, including hydrogel-enhanced and platinum-tungsten designs, can cost several thousand USD per procedure. In many middle-income healthcare systems, these costs can exceed available reimbursement. The gap between device costs and reimbursement can limit adoption, even when clinical need is high. Consequently, coil uptake remains uneven across countries with varying payment systems and is concentrated in locations with stronger reimbursement frameworks and established referral pathways.

Cost is not the only barrier to premium coil adoption. A prospective, multicenter, randomized trial, with follow-up completed in February 2025, found that operators rated bare platinum coils easier to manipulate than second-generation hydrogel designs, with scores of 8.8 and 6.3, respectively, on a 10-point scale.^{[2]Park J, et al., “Comparison of Second-Generation Hydrogel Embolic Coils and Bare Platinum Coils in Ruptured Intracranial Aneurysm Treatment,” Neurosurgical Review,} Higher-priced systems must therefore demonstrate clear procedural or clinical benefits. Group purchasing arrangements also increase price pressure, limiting pricing flexibility for manufacturers and new entrants. Vendors must support premium pricing through clinical evidence, workflow advantages, or differentiated clinical applications.

Requirements for Highly Specialized Operators and Infrastructure

Coil embolization requires specialized training, appropriate angiography equipment, and supporting clinical services. Complex neurovascular cases may require neurointerventional or vascular intervention training, biplane fluoroscopy, and intraoperative neuromonitoring capabilities. Few facilities possess all these resources, limiting the number of locations that can routinely perform advanced coiling procedures. This constraint is particularly evident in healthcare systems developing stroke and interventional care networks.

Hospitals may procure imaging equipment before employing clinicians who can perform complex coiling procedures, creating procurement interest without immediate procedure volumes. The shortage of interventional neurology specialists also encourages suppliers to simplify deployment systems. Easier-to-use products may reduce operational barriers, provided they maintain acceptable clinical outcomes. Training constraints, concerns over particulate shedding and long-term safety, and limited direct comparisons among coil designs can delay procurement decisions and slow the transition from familiar bare-platinum products.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Deployment Type: Detachable Systems Lead While Pushable Coils Serve Expanding Peripheral Uses

Detachable coils held a 61.45% share of the embolization coils market in 2025. Their ability to reposition coils and confirm stability before electrolytic or mechanical detachment supports precise vessel occlusion in wide-neck aneurysms and high-flow arteriovenous fistulae. This capability enables physicians to adjust placement before final release in anatomically complex cases.

Suppliers must offer a range of diameters, softness levels, and delivery options to address the segment’s large installed base. Product breadth can support standardized purchasing across framing, filling, and finishing stages. Pushable coils are the fastest-growing deployment type, with a projected CAGR of 7.22% from 2026 to 2031, driven by oncology and gastrointestinal hemorrhage procedures that prioritize speed and cost efficiency.

By Material: Bare Platinum Retains Scale While Platinum-Tungsten Gains Momentum

Bare platinum coils held a 41.67% revenue share in 2025, supported by extensive clinical use, documented safety, and compatibility with existing microcatheter inventories. Physician familiarity and established procurement relationships further reinforce demand. Bare platinum remains the standard benchmark for evaluating newer coil technologies.

Platinum-tungsten alloy coils are forecast to grow at a CAGR of 7.56% through 2031. Higher radiopacity, thinner wire gauges, improved packing density, and three-dimensional conformability support detailed visualization and controlled filling in complex anatomy. This design approach has been commercialized in more than 30 countries, supporting adoption in neurovascular and peripheral procedures.

By Application: Neurovascular Procedures Remain Largest While Peripheral Vascular Disease Grows Fastest

Neurovascular applications accounted for a 42.78% share of the embolization coils market in 2025. The category includes intracranial aneurysms, arteriovenous malformations, carotid cavernous fistulae, and middle meningeal artery embolization for chronic subdural hematoma. These cases often require five to 15 coils per aneurysm, supporting segment value through high device use and premium pricing.

Peripheral vascular disease is the fastest-growing application, with a projected CAGR of 8.98% from 2026 to 2031. Growth is driven by treatment for splenic artery aneurysms, uterine fibroid embolization, prostate artery embolization, and post-EVAR sac embolization. As these procedures expand coil use beyond neurovascular care, the peripheral vascular disease segment is expected to outpace overall market growth during the forecast period.

By End User: Hospitals Hold the Largest Position as Ambulatory Surgical Centers Expand

Hospitals held a 56.44% share of the embolization coils market in 2025. Their position reflects the complexity of neurovascular coiling, which may require biplane angiography, neuroanesthesia, and immediate neurosurgical backup. Academic and tertiary hospitals also concentrate clinical expertise and procedure volumes through interventional radiology and neurovascular fellowship training programs.

Ambulatory surgical centers are forecast to grow at a CAGR of 8.20% from 2026 to 2031. Medicare coverage expansion for interventional radiology-adjacent procedures in the 2026 covered procedures list created a reimbursement pathway for selected peripheral embolization procedures in lower-cost outpatient settings. However, complex neurovascular coiling is expected to remain concentrated in hospitals.

Geography Analysis

North America held 40.40% of the embolization coils market share in 2025, supported by comprehensive stroke centers, third-party reimbursement, and an established interventional radiology workforce. A six-year national assessment reported 103,355 endovascular therapy procedures among 867,335 acute ischemic stroke hospitalizations in the United States, representing an 11.9% utilization rate. Canada standardizes aneurysm care through provincial stroke networks, while Mexico is expanding neurovascular capacity through public and private hospital modernization.

Germany, the United Kingdom, France, Italy, and Spain support the European market through the integration of coil embolization into national stroke care pathways. The EU Medical Device Regulation creates entry barriers for smaller companies, while established suppliers with CE certification are better positioned to retain market access. Japan remains a premium market and regulatory reference point, with Terumo Neuro receiving PMDA approval for WovenEndoBridge 17 in November 2025 and launching it commercially in May 2026.

Asia-Pacific is projected to record the fastest regional CAGR of 7.90% from 2026 to 2031, driven by mature interventional radiology systems in Japan and South Korea and increasing procedure volumes in China. India is strengthening institutional capacity, with equipment availability, training, and pricing remaining key adoption factors. MicroPort NeuroScientific launched the NUMEN Coil Embolization System in Egypt in August 2025 through its partnership with PentaMed, expanding access to Middle East and Africa markets.